Oxymetholone

Summary

Oxymetholone (CHEMBL1200585) is an approved small molecule (ATC A14AA05).

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: A14AA05
• Chemistry: 332.5 Da · C21H32O3

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1200585
Name	Oxymetholone
Type	Small molecule
Max phase	4
FDA approved	no
PubChem CID	5281034
ATC	A14AA05
Molecular formula	C21H32O3
Molecular weight	332.5
InChIKey	ICMWWNHDUZJFDW-DHODBPELSA-N

SMILES: C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@]2(C)O)CC[C@@H]4[C@@]3(C/C(=C/O)/C(=O)C4)C

IUPAC name: (2Z,5S,8R,9S,10S,13S,14S,17S)-17-hydroxy-2-(hydroxymethylidene)-10,13,17-trimethyl-1,4,5,6,7,8,9,11,12,14,15,16-dodecahydrocyclopenta[a]phenanthren-3-one

Also known as: Adroyd, Anadrol-50, Anapolon, Anapolon 50, Anasteron, CI-406, HMD, NSC-26,198, NSC-26198, Oximetholone, Oximetolona, Oxymetholone

Patent coverage: 1,514 distinct patent families (5,113 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 20 (assay-derived). Sample: Tyrosyl-DNA phosphodiesterase 1, Microtubule-associated protein tau, Nuclear receptor ROR-gamma, Prelamin-A/C, Beta-lactamase, Glucocorticoid receptor, Progesterone receptor, Type-1 angiotensin II receptor, Prostaglandin G/H synthase 2, Adenosine receptor A3.

Bioactivity

ChEMBL activities: 10 potent at pChembl ≥ 5 of 25 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
ALDH1A1	7.15	Potency	70.8	nM	CHEMBL_ACT_4128102
P15207	6.86	Ki	137	nM	CHEMBL_ACT_7721227
P15207	6.69	IC50	206	nM	CHEMBL_ACT_7721226
P15207	6.07	AC50	850	nM	CHEMBL_ACT_25233054
P15917	5.4	Potency	3981	nM	CHEMBL_ACT_4647862
TDP1	5.25	Potency	5623	nM	CHEMBL_ACT_3934583
NPSR1	5.2	Potency	6310	nM	CHEMBL_ACT_4900731
ADORA3	5.09	AC50	8200	nM	CHEMBL_ACT_25134572
PTGS2	5.04	AC50	9200	nM	CHEMBL_ACT_25166540
P51450	5	Potency	10000	nM	CHEMBL_ACT_4094108

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

0 indications (0 at ChEMBL trial phase 4).

Clinical trials

Total trials: 0.

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).